Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06706817 · ClinicalTrials.gov registry record · Phase 3

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
180
Enrollment target
20
Study locations

NCT06706817: Recruiting Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca.

NCT06706817 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 180 participants, above the 126-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (43% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06706817, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
180 participants
Enrollment target
20
Study locations

Study Summary

The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. The visit frequency will be once every 4 weeks (Q4W).

Primary Outcome

Changes from baseline in participant-reported nasal congestion as evaluated by the nasal congestion score (NCS) as part of the nasal polyposis symptom diary (NPSD) following initiation of tezepelumab treatment.

Conditions Studied

Chronic Rhinosinusitis With Nasal Polyps

Interventions

  • COMBINATION_PRODUCT Tezepelumab

Study Locations (20)

Other

  • Research Site - Plovdiv
  • Research Site - Sofia
  • Research Site - Sofia
  • Research Site - Le Kremlin-Bicêtre
  • Research Site - Lille
  • Research Site - Marseille
  • Research Site - Nantes
  • Research Site - Pierre-Bénite
  • Research Site - Poitiers
  • Research Site - Toulouse
  • Research Site - Düsseldorf
  • Research Site - Marburg
  • Research Site - Tübingen

Quebec

  • Research Site - Québec
  • Research Site - Québec

California

  • Research Site - Newport Beach

Illinois

  • Research Site - Chicago

Massachusetts

  • Research Site - Chestnut Hill

Missouri

  • Research Site - Columbia

Ontario

  • Research Site - Hamilton

Trial Details

FieldValue
Enrollment Target 180 participants
Start Date 2024-12-03
Est. Completion 2027-01-13
Phase Phase 3
AstraZeneca

1,285 total trials

What NCT06706817 shows while recruiting

NCT06706817 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 126-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (43% higher).

The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 1 intervention - of which Tezepelumab is the first listed.

NCT06706817 names 20 study sites across 7 states, led by Other, Quebec, California.

Frequently Asked Questions

What is clinical trial NCT06706817 about?

NCT06706817 is a clinical study titled "A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab". The main objective of this study is to evaluate treatment outcomes of tezepelumab among participants with physician-determined surgery-eligible CRSwNP, with or without asthma. Study details include: 1. The study duration will be up to 40 weeks. 2. The treatment duration will be up to 24 weeks. 3. ...

What is the current status of trial NCT06706817?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2024-12-03. Estimated completion is 2027-01-13.

What conditions does trial NCT06706817 study?

This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.

What interventions are being tested in trial NCT06706817?

The interventions under investigation include: Tezepelumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT06706817?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06706817 being conducted?

This trial has 20 study locations across California, Illinois, Massachusetts, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Rhinosinusitis With Nasal Polyps

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06706817's enrollment target sits among peer trials

180 5th of 11 higher than 7 of 11 other Chronic Rhinosinusitis With Nasal Polyps trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Rhinosinusitis With Nasal Polyps trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01558804 · 180 participants

    GRoup A StrePtococcus

  • NCT02932176 · 180 participants

    Machine Learning for Handheld Vascular Studies

  • NCT03384563 · 180 participants · Phase 4

    Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

  • NCT03423628 · 180 participants · Phase 1

    A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06706817

Source: ClinicalTrials.gov NCT06706817, the US trial registry maintained by the National Library of Medicine. NCT06706817 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.